Publications published since 2010 from OUS - Section for Breast Oncology

192 publications found

Publications 2022

1. Merklinger-Gruchala A, Jasienska G, Thune I, Kapiszewska M (2022)
   Joint effect of particulate matter and cigarette smoke on women's sex hormones
   BMC Womens Health, 22 (1), 3
   DOI 10.1186/s12905-021-01586-w
2. Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2022)
   Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
   Int. J. Cancer, 150 (1), 100-111
   DOI 10.1002/ijc.33768

Publications 2021

1. Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L (2021)
   Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
   Mol. Oncol., 15 (8), 2026-2045
   DOI 10.1002/1878-0261.12951
2. Brunvoll SH, Thune I, Bertheussen GF, Fjeldheim F, Flote VG, Frydenberg H, Lundgren S, Skjerven H, Lomo J, Fagerland MW, McTiernan A, Schlichting E, Hjartaker A (2021)
   Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery
   Br. J. Nutr., 125 (2), PII S0007114520002627-182
   DOI 10.1017/S0007114520002627
3. Dahl AA, Kiserud CE, Fossa SD, Loge JH, Reinertsen KV, Ruud E, Lie HC (2021)
   A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study)
   Cancers, 13 (22), 5800
   DOI 10.3390/cancers13225800
4. Engebraaten O, Yau C, Berg K, Borgen E, Garred O, Berstad MEB, Fremstedal ASV, De Michele A, van't Veer L, Esserman L, Weyergang A (2021)
   RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
   Nat. Commun., 12 (1), 6427
   DOI 10.1038/s41467-021-26018-z
5. Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Ryden L, Fehm T, Aft R, Sola M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Ferno M, Krawczyk N, Weilbaecher K, Margeli M, Hahn M et al. (2021)
   Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
   Eur. J. Cancer, 154, 128-137
   DOI 10.1016/j.ejca.2021.06.028
6. Helland T, Naume B, Hustad S, Bifulco E, Kvaloy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Soiland H (2021)
   Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
   Mol. Oncol., 15 (4), 957-967
   DOI 10.1002/1878-0261.12865
7. Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, Naume B, Wiedswang G (2021)
   Preoperative CTC-Detection by CellSearch(R) Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer
   Cancers, 13 (3), 485
   DOI 10.3390/cancers13030485
8. Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G (2021)
   In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
   Breast Cancer Res., 23 (1), 17
   DOI 10.1186/s13058-021-01393-z
9. Kruger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred O, Naume B, Engebraaten O, Akslen LA (2021)
   Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
   Sci Rep, 11 (1), 3388
   DOI 10.1038/s41598-021-81914-0
10. Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang JP, Johnson J, Russnes HG, Bravo-Cordero JJ, Birbrair A, Naume B, Azhar M, Frenette PS, Aguirre-Ghiso JA (2021)
    Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGF-beta 2
    Nat. Cancer, 2 (3), 327-+
    DOI 10.1038/s43018-021-00179-8
11. Pandya AD, Iversen TG, Moestue S, Grinde MT, Morch Y, Snipstad S, Aslund AKO, Oy GF, Kildal W, Engebraten O, Sandvig K, Skotland T, Maelandsmo GM (2021)
    Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
    Nanomaterials, 11 (5), 1140
    DOI 10.3390/nano11051140
12. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F et al. (2021)
    Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
    Breast, 59, 327-338
    DOI 10.1016/j.breast.2021.07.021
13. Stikbakke E, Schirmer H, Knutsen T, Stoyten M, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Richardsen E, Thune I (2021)
    Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study
    Cancer Med.
    DOI 10.1002/cam4.4523
14. Vandraas KF, Reinertsen KV, Kiserud CE, Lie HC (2021)
    Fear of cancer recurrence among young adult cancer survivors-exploring long-term contributing factors in a large, population-based cohort
    J. Cancer Surviv.-Res. Pract., 15 (4), 497-508
    DOI 10.1007/s11764-020-00943-2

Publications 2020

1. Falstie-Jensen AM, Esen BO, Kjaersgaard A, Lorenzen EL, Jensen JD, Reinertsen KV, Dekkers OM, Ewertz M, Cronin-Fenton DP (2020)
   Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study
   Breast Cancer Res., 22 (1), 106
   DOI 10.1186/s13058-020-01337-z
2. Frydenberg H, Harsem NK, Ofigsbo A, Skoglund H, Braendengen M, Kaasa S, Guren MG (2020)
   Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
   Clin. Colorectal Canc., 19 (2), 141-144
   DOI 10.1016/j.clcc.2020.02.013
3. Gythfeldt HV, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred O, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Borresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
   Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment ofER-positive breast cancer
   Int. J. Cancer, 147 (9), 2515-2525
   DOI 10.1002/ijc.33108
4. Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G (2020)
   Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma
   Ann. Surg., 271 (3), 549-558
   DOI 10.1097/SLA.0000000000003035
5. Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjorklund SS, Bofin AM, Maelandsmo GM, Sorlie T, Mortensen ES, Perander M, Geisler J, Hofvind S, Bathen TF, Borgen E, Borresen-Dale AL, Engebraten O, Garred O, Geitvik GA, Langerod A, Naume B, Russnes HG et al. (2020)
   The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
   Sci Rep, 10 (1), 1277
   DOI 10.1038/s41598-020-57759-4
6. Kyte JA, Andresen NK, Russnes HG, Fretland SO, Falk RS, Lingjaerde OC, Naume B (2020)
   ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
   J. Transl. Med., 18 (1), 269
   DOI 10.1186/s12967-020-02421-w
7. Kyte JA, Rossevold A, Falk RS, Naume B (2020)
   ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
   J. Transl. Med., 18 (1), 252
   DOI 10.1186/s12967-020-02424-7
8. Lofterod T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, Akslen LA, Reitan JB, Wilsgaard T, Thune I (2020)
   Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study
   Breast Cancer Res. Treat., 182 (1), 215-227
   DOI 10.1007/s10549-020-05679-2
9. Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Moller B (2020)
   Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
   BMC Cancer, 20 (1), 488
   DOI 10.1186/s12885-020-06979-y
10. Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeodegard GF, Tasken KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred O, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2020)
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
    Int. J. Cancer, 146 (1), 223-235
    DOI 10.1002/ijc.32638
11. Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan O, Liestol K, Vitelli V, Frigessi A, Langerod A, Mathelier A, Engebraten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Borresen-Dale AL, Russnes HG, Lingjaerde OC, OSBREAC (2020)
    DNA copy number motifs are strong and independent predictors of survival in breast cancer
    Commun. Biol., 3 (1), 153
    DOI 10.1038/s42003-020-0884-6
12. Stikbakke E, Richardsen E, Knutsen T, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Thune I (2020)
    Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study
    Int. J. Cancer, 147 (1), 84-92
    DOI 10.1002/ijc.32718

Publications 2019

1. Dahl AA, Foss SD, Lie HC, Loge JH, Reinertsen KV, Ruud E, Kiserud CE (2019)
   Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors
   J. Adolesc. Young Adult Oncol., 8 (3), 304-311
   DOI 10.1089/jayao.2018.0109
2. Debik J, Euceda LR, Lundgren S, Gythfeldt HV, Garred O, Borgen E, Engebraaten O, Bathen TF, Giskeodegard GF (2019)
   Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
   J. Proteome Res., 18 (10), 3649-3660
   DOI 10.1021/acs.jproteome.9b00316
3. Dork T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL et al. (2019)
   Two truncating variants in FANCC and breast cancer risk
   Sci Rep, 9, 12524
   DOI 10.1038/s41598-019-48804-y
4. Falstie-Jensen AM, Kjaersgaard A, Lorenzen EL, Jensen JD, Reinertsen KV, Dekkers OM, Ewertz M, Cronin-Fenton DP (2019)
   Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study
   Breast Cancer Res., 21, 44
   DOI 10.1186/s13058-019-1122-3
5. Hartmann-Johnsena OJ, Karesen R, Schlichting E, Naume B, Nygard JF (2019)
   Using clinical cancer registry data for estimation of quality indicators: Results from the Norwegian breast cancer registry
   Int. J. Med. Inform., 125, 102-109
   DOI 10.1016/j.ijmedinf.2019.03.004
6. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Luders T, Engebraaten O, Borresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2019)
   Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
   OncoImmunology, 8 (2), e1537691
   DOI 10.1080/2162402X.2018.1537691
7. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred O, Boekel J, Sauer T, Zhao W, Nord S, Hoglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
   Breast cancer quantitative proteome and proteogenomic landscape
   Nat. Commun., 10, 1600
   DOI 10.1038/s41467-019-09018-y
8. Kyte JA, Fane A, Pule M, Gaudernack G (2019)
   Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
   OncoImmunology, 8 (4), e1565236
   DOI 10.1080/2162402X.2019.1565236
9. Lai XR, Geier OM, Fleischer T, Garred Y, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Borresen-Dale AL, Kristensen VN, Engebraaten O, Kohn-Luque A, Frigessi A (2019)
   Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
   Cancer Res., 79 (16), 4293-4304
   DOI 10.1158/0008-5472.CAN-18-1804
10. Lindholm EM, Aure MR, Haugen MH, Sahlberg KK, Kristensen VN, Nebdal D, Borresen-Dale AL, Lingjrde OC, Engebraaten O (2019)
    miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
    Mol. Oncol., 13 (10), 2278-2296
    DOI 10.1002/1878-0261.12561
11. Nilssen Y, Brustugun OT, Eriksen MT, Gulbrandsen J, Haug ES, Naume B, Moller B (2019)
    Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway
    Cancer Epidemiol., 61, 59-69
    DOI 10.1016/j.canep.2019.05.004
12. Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge O, Fossa A, Holte H, Lund MB, Murbraech K, Reinertsen KV, Stenehjem JS, Kiserud CE (2019)
    Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
    Bone Marrow Transplant., 54 (4), 607-610
    DOI 10.1038/s41409-018-0342-y
13. Tekpli X, Lien T, Rossevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred O, Frigessi A, Sahlberg KK, Sorlie T, Russnes HG, Naume B, Kristensen VN, Borresen-Dale AL, Schlichting E, Sauer T, Geisler J, Hofvind S, Bathen TF et al. (2019)
    An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
    Nat. Commun., 10, 5499
    DOI 10.1038/s41467-019-13329-5

Publications 2018

1. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martinez J, Onstenk W et al. (2018)
   Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
   JNCI-J. Natl. Cancer Inst., 110 (6), djy018-567
   DOI 10.1093/jnci/djy018
2. Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lonning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B (2018)
   NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
   Breast Cancer Res., 20, 120
   DOI 10.1186/s13058-018-1049-0
3. Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, Bjerve KS, Hjartaker A (2018)
   Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment
   Nutr. J., 17, 94
   DOI 10.1186/s12937-018-0402-6
4. Eide HA, Knudtsen IS, Sandhu V, Londalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland A (2018)
   Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
   Adv. Radiat. Oncol., 3 (2), 130-138
   DOI 10.1016/j.adro.2017.12.007
5. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland A (2018)
   Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
   Acta Oncol., 57 (9), 1225-1231
   DOI 10.1080/0284186X.2018.1465585
6. Hoglander EK, Nord S, Wedge DC, Lingjaerde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred O, Holmen MM, Wist E, Naume B, Van Loo P, Borresen-Dale AL, Engebraaten O, Kristensen V (2018)
   Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
   Genome Med., 10, 92
   DOI 10.1186/s13073-018-0601-y
7. Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Luders T, Gythfeldt HV, Troyanskaya O, Kyte JA, Borresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
   Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
   OncoImmunology, 7 (11)
   DOI 10.1080/2162402X.2018.1457598
8. Lofterod T, Mortensen ES, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T, Eggen AE, McTiernan A, Aziz S, Wist EA, Stensvold A, Reitan JB, Akslen LA, Thune I (2018)
   Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes
   BMC Cancer, 18, 654
   DOI 10.1186/s12885-018-4568-2
9. Madssen TS, Thune I, Flote VG, Lundgren S, Bertheussen GF, Frydenberg H, Wist E, Schlichting E, Schafer H, Fjosne HE, Vettukattil R, Lomo J, Bathen TF, Giskeodegard GF (2018)
   Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment
   Br. J. Cancer, 119 (9), 1144-1154
   DOI 10.1038/s41416-018-0211-x
10. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang WW, Palacios D, Almasbak H, Bajor M, Clement D, Brandt L, Onfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
    Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
    Cancer Immunol. Res., 6 (4), 467-480
    DOI 10.1158/2326-6066.CIR-17-0207
11. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Borresen-Dale AL, Engebraten O, Maelandsmo GM, Oslo Breast Canc Res Consortium (2018)
    Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
    Mol. Oncol., 12 (9), 1540-1558
    DOI 10.1002/1878-0261.12319
12. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Borresen-Dale AL, Helland A, Markowetz F, Russnes HG (2018)
    Intratumor heterogeneity defines treatment-resistant HER2+breast tumors
    Mol. Oncol., 12 (11), 1838-1855
    DOI 10.1002/1878-0261.12375
13. Seip K, Jorgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Maelandsmo GM, Prasmickaite L (2018)
    Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
    Cancer Lett., 439, 1-13
    DOI 10.1016/j.canlet.2018.09.023

Publications 2017

1. Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HKM, Luders T, Rodland E, Vaske CJ, Zhao W, Moller EK, Nord S, Giskeodegard GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IRK, Naume B, Schlichting E et al. (2017)
   Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
   Breast Cancer Res., 19, 44
   DOI 10.1186/s13058-017-0812-y
2. Bjorklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnaes GIG, Toppmeyer D, Riis M, Naume B, Borresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G (2017)
   Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
   Sci Rep, 7, 5568
   DOI 10.1038/s41598-017-05537-0
3. Broughton MN, Westgaard A, Paus E, Oijordsbakken M, Henanger KJ, Naume B, Bjoro T (2017)
   Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
   Tumor Biol., 39 (6), 707436-11
   DOI 10.1177/1010428317707436
4. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland A, Naume B, Caldas C, Borresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
   Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
   Oncotarget, 8 (34), 57121-57133
   DOI 10.18632/oncotarget.19078
5. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Naume B, Borgen E, Maelandsmo GM, Oslo Breast Canc Consortium (2017)
   Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
   Breast Cancer Res. Treat., 162 (1), 127-137
   DOI 10.1007/s10549-016-4096-1
6. Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
   Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
   Metabolomics, 13 (4), 37
   DOI 10.1007/s11306-017-1168-0
7. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Alnaes GIG, Riis MLH, Helland A, Hautaniemi S, Lonning PE, Naume B, Borresen-Dale AL, Tost J, Kristensen VN (2017)
   DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
   Oncotarget, 8 (1), 1074-1082
   DOI 10.18632/oncotarget.13718
8. Fleischer T, Tekpli X, Mathelier A, Wang SX, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Borresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN, Oslo Breast Canc Res Consortium OS (2017)
   DNA methylation at enhancers identifies distinct breast cancer lineages
   Nat. Commun., 8, 1379
   DOI 10.1038/s41467-017-00510-x
9. Gingras I, Holmes E, De Azambuja E, Nguyen DHA, Izquierdo M, Zujewski JA, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA (2017)
   Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
   JNCI-J. Natl. Cancer Inst., 109 (8), djw331
   DOI 10.1093/jnci/djw331
10. Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaloy JT, Lash TL, Alns GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Soiland H (2017)
    Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
    Breast Cancer Res., 19, 125
    DOI 10.1186/s13058-017-0916-4
11. Juvet LK, Thune I, Elvsaas IKO, Fors EA, Lundgren S, Bertheussen G, Leivseth G, Oldervoll LM (2017)
    The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta-analysis
    Breast, 33, 166-177
    DOI 10.1016/j.breast.2017.04.003
12. Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Maelandsmo GM, Malinen E (2017)
    Dynamic 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
    Mol. Imaging. Biol., 19 (2), 271-279
    DOI 10.1007/s11307-016-0998-x
13. Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sorlie T, Russnes HG, Naume B (2017)
    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Breast Cancer Res., 19, 120
    DOI 10.1186/s13058-017-0911-9
14. Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjoro T, Kiserud CE (2017)
    Fatigue During and After Breast Cancer Therapy-A Prospective Study
    J. Pain Symptom Manage., 53 (3), 551-560
    DOI 10.1016/j.jpainsymman.2016.09.011
15. Reinertsen KV, Loge JH, Brekke M, Kiserud CE (2017)
    Chronic fatigue in adult cancer survivors
    Tidsskr. Nor. Laegeforen., 137 (21), 1701-1704
16. Saldova R, Haakensen VD, Rodland E, Walsh I, Stockmann H, Engebraaten O, Borresen-Dale AL, Rudd PM (2017)
    Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
    Mol. Oncol., 11 (10), 1361-1379
    DOI 10.1002/1878-0261.12105
17. Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjornbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G (2017)
    Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
    Ann. Surg. Oncol., 24 (8), 2113-2121
    DOI 10.1245/s10434-017-5818-2
18. Silwal-Pandit L, Nord S, Gythfeldt HV, Moller EK, Fleischer T, Rodland E, Krohn M, Borgen E, Garred O, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Stokke MN, Vollan HKM, Kristensen V, Langerod A, Lundgren S, Wist E, Naume B, Lingjaerde OC, Borresen-Dale AL et al. (2017)
    The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
    Clin. Cancer Res., 23 (16), 4662-4670
    DOI 10.1158/1078-0432.CCR-17-0160
19. Vaysse C, Lomo J, Garred O, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husoy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
    Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer (vol 3, 35, 2017)
    npj Breast Cancer, 3, 35
    DOI 10.1038/s41523-017-0030-x

Publications 2016

1. Bandera EV, Fay SH, Giovannucci E, Leitzmann MF, Marklew R, McTiernan A, Mullee A, Romieu I, Thune I, Uauy R, Wiseman MJ, World Canc Res Fund Int (2016)
   The use and interpretation of anthropometric measures in cancer epidemiology: A perspective from the world cancer research fund international continuous update project
   Int. J. Cancer, 139 (11), 2391-2397
   DOI 10.1002/ijc.30248
2. Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A (2016)
   Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
   eCancerMedicalScience, 10, 691
   DOI 10.3332/ecancer.2016.691
3. Davidson B, Reinertsen KV, Trinh D, Reed W, Bohler PJ (2016)
   BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma
   Hum. Pathol., 54, 64-73
   DOI 10.1016/j.humpath.2016.02.023
4. Demeulemeester J, Kumar P, Moller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Esteki MZ, Theunis K, Gallardo EF, Grundstad AJ, Borgen E, Baumbusch LO, Borresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B (2016)
   Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
   Genome Biol., 17, 250
   DOI 10.1186/s13059-016-1109-7
5. Eide HA, Halvorsen AR, Sandhu V, Fane A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland A (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin. Transl. Immunol., 5, e109
   DOI 10.1038/cti.2016.65
6. Fjeldheim FN, Frydenberg H, Flote VG, McTiernan A, Furberg AS, Ellison PT, Barrett ES, Wilsgaard T, Jasienska G, Ursin G, Wist EA, Thune I (2016)
   Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes
   BMC Cancer, 16, 776
   DOI 10.1186/s12885-016-2804-1
7. Flote VG, Vettukattil R, Bathen TF, Egeland T, McTiernan A, Frydenberg H, Husoy A, Finstad SE, Lomo J, Garred O, Schlichting E, Wist EA, Thune I (2016)
   Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer
   Lipids Health Dis., 15, 56
   DOI 10.1186/s12944-016-0225-4
8. Frydenberg H, Thune I, Lofterod T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, Akslen LA, McTiernan A (2016)
   Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival
   Breast Cancer Res. Treat., 155 (2), 345-354
   DOI 10.1007/s10549-015-3671-1
9. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Borresen-Dale AL, Yakhini Z (2016)
   Serum N-glycan analysis in breast cancer patients - Relation to tumour biology and clinical outcome
   Mol. Oncol., 10 (1), 59-72
   DOI 10.1016/j.molonc.2015.08.002
10. Iversen A, Frydenberg H, Furberg AS, Flote VG, Finstad SE, McTiernan A, Ursin G, Wilsgaard T, Ellison PT, Jasienska G, Thune I (2016)
    Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women
    Eur. J. Cancer Prev., 25 (1), 9-18
    DOI 10.1097/CEJ.0000000000000130
11. Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VCG, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P (2016)
    Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
    Ann. Oncol., 27 (9), 1719-1725
    DOI 10.1093/annonc/mdw249
12. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Walchli S, Pule M (2016)
    T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
    OncoImmunology, 5 (12), e1249090
    DOI 10.1080/2162402X.2016.1249090
13. Kyte JA, Aamdal S, Dueland S, Saeboe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
    Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
    OncoImmunology, 5 (11), e1232237
    DOI 10.1080/2162402X.2016.1232237
14. Laake I, Larsen IK, Selmer R, Thune I, Veierod MB (2016)
    Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study
    BMC Cancer, 16, 402
    DOI 10.1186/s12885-016-2445-4
15. Marcinkowska UM, Ellison PT, Galbarczyk A, Milkowska K, Pawlowski B, Thune I, Jasienska G (2016)
    Lack of support for relation between woman's masculinity preference, estradiol level and mating context
    Horm. Behav., 78, 1-7
    DOI 10.1016/j.yhbeh.2015.10.012

Publications 2015

1. Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
   Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
   Gene Ther., 22 (5), 391-403
   DOI 10.1038/gt.2015.4
2. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad O, Dueland S (2015)
   Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
   Br. J. Cancer, 113 (11), 1548-1555
   DOI 10.1038/bjc.2015.380
3. Barrett ES, Chen CS, Thurston SW, Haug LS, Sabaredzovic A, Fjeldheim FN, Frydenberg H, Lipson SF, Ellison PT, Thune I (2015)
   Perfluoroalkyl substances and ovarian hormone concentrations in naturally cycling women
   Fertil. Steril., 103 (5), 1261-+
   DOI 10.1016/j.fertnstert.2015.02.001
4. Barrett ES, Tran V, Thurston SW, Frydenberg H, Lipson SF, Thune I, Ellison PT (2015)
   Women who are married or living as married have higher salivary estradiol and progesterone than unmarried women
   Am. J. Hum. Biol., 27 (4), 501-507
   DOI 10.1002/ajhb.22676
5. Bjorklund SS, Kristensen VN, Seiler M, Kumar S, Alnaes GIG, Ming Y, Kerrigan J, Naume B, Sachidanandam R, Bhanot G, Borresen-Dale AL, Ganesan S (2015)
   Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas
   BMC Cancer, 15, 524
   DOI 10.1186/s12885-015-1510-8
6. Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjornbeth BA, Borgen E, Naume B, Waage A, Wiedswang G (2015)
   Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases
   Ann. Surg. Oncol., 22 (12), 4029-4037
   DOI 10.1245/s10434-015-4482-7
7. Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebraten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2015)
   In Vivo P-31 Magnetic Resonance Spectroscopic Imaging (MRSI) for Metabolic Profiling of Human Breast Cancer Xenografts
   J. Magn. Reson. Imaging, 41 (3), 601-609
   DOI 10.1002/jmri.24588
8. Flote VG, Frydenberg H, Ursin G, Iversen A, Fagerland MW, Ellison PT, Wist EA, Egeland T, Wilsgaard T, McTiernan A, Furberg AS, Thune I (2015)
   High-Density Lipoprotein-Cholesterol, Daily Estradiol and Progesterone, and Mammographic Density Phenotypes in Premenopausal Women
   Cancer Prev. Res., 8 (6), 535-544
   DOI 10.1158/1940-6207.CAPR-14-0267
9. Frydenberg H, Flote VG, Larsson IM, Barrett ES, Furberg AS, Ursin G, Wilsgaard T, Ellison PT, McTiernan A, Hjartaker A, Jasienska G, Thune I (2015)
   Alcohol consumption, endogenous estrogen and mammographic density among premenopausal women
   Breast Cancer Res., 17, 103
   DOI 10.1186/s13058-015-0620-1
10. Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
    Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
    Cancer Immunol. Immunother., 64 (12), 1609-1621
    DOI 10.1007/s00262-015-1766-5
11. Jasienska G, Ellison PT, Galbarczyk A, Jasienski M, Kalemba-Drozdz M, Kapiszewska M, Nenko I, Thune I, Ziomkiewicz A (2015)
    Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: a case of antagonistic pleiotropy?
    Proc. R. Soc. B-Biol. Sci., 282 (1803), 20142395
    DOI 10.1098/rspb.2014.2395
12. Klimek M, Galbarczyk A, Colleran H, Thune I, Ellison PT, Ziomkiewicz A, Jasienska G (2015)
    Digit ratio (2D:4D) does not correlate with daily 17 beta-estradiol and progesterone concentrations in healthy women of reproductive age
    Am. J. Hum. Biol., 27 (5), 667-673
    DOI 10.1002/ajhb.22717
13. Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Lokkevik E, Lundgren S, Ostenstad B, Risberg T, Mjaaland I, Aas T, Lonning PE (2015)
    Concomitant inactivation of the p53-and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
    Mol. Oncol., 9 (8), 1553-1564
    DOI 10.1016/j.molonc.2015.04.008
14. Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Bin Tian MH, Gunaratne J, Engebraaten O, Manley JL, Borresen-Dale AL, Neilsen PM, Prives C (2015)
    Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
    Genes Dev., 29 (12), 1298-1315
    DOI 10.1101/gad.263202.115
15. Rye IH, Lundin P, Maner S, Fjelldal R, Naume B, Wigler M, Hicks J, Borresen-Dale AL, Zetterberg A, Russnes HG (2015)
    Quantitative Multigene FISH on Breast Carcinomas Identifies der(1;16)(q10;p10) as an Early Event in Luminal A Tumors
    Gene Chromosomes Cancer, 54 (4), 235-248
    DOI 10.1002/gcc.22237
16. Sahlberg KK, Bottai G, Naume B, Burwinkel B, Calin GA, Borresen-Dale AL, Santarpia L (2015)
    A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
    Clin. Cancer Res., 21 (5), 1207-1214
    DOI 10.1158/1078-0432.CCR-14-2011
17. Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjornbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015)
    Circulating Tumor Cells in Patients With Colorectal Liver Metastasis Predict Impaired Survival
    Ann. Surg., 261 (1), 164-171
    DOI 10.1097/SLA.0000000000000580
18. Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Vollan HKM, Schlichting E, Karesen R, Naume B, Borresen-Dale AL, Farnebo M, Langerod A (2015)
    The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
    PLoS One, 10 (10), e0139965
    DOI 10.1371/journal.pone.0139965

Publications 2014

1. Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Rosenblatt DN, Thune I, Vieira R, Norat T (2014)
   Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
   Ann. Oncol., 25 (10), 1901-1914
   DOI 10.1093/annonc/mdu042
2. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014)
   A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
   Breast Cancer Res. Treat., 145 (2), 411-418
   DOI 10.1007/s10549-014-2939-1
3. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2014)
   Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
   Int. J. Cancer, 134 (1), 102-113
   DOI 10.1002/ijc.28338
4. Esmaeili M, Bathen TF, Engebraten O, Maelandsmo GM, Gribbestad IS, Moestue SA (2014)
   Quantitative P-31 HR-MAS MR Spectroscopy for Detection of Response to PI3K/mTOR Inhibition in Breast Cancer Xenografts
   Magn. Reson. Med., 71 (6), 1973-1981
   DOI 10.1002/mrm.24869
5. Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Borresen-Dale AL, Kristensen VN, Tost J (2014)
   Integrated analysis of high- resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients
   Int. J. Cancer, 134 (11), 2615-2625
   DOI 10.1002/ijc.28606
6. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis MLH, Haakensen VD, Warnberg F, Naume B, Helland A, Borresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   Genome Biol., 15 (8), 435
   DOI 10.1186/s13059-014-0435-x
7. Flote VG, Furberg AS, McTiernan A, Frydenberg H, Ursin G, Iversen A, Lofteroed T, Ellison PT, Wist EA, Egeland T, Wilsgaard T, Makar KW, Chang-Claude J, Thune I (2014)
   Gene variations in oestrogen pathways, CYP19A1, daily 17 beta-estradiol and mammographic density phenotypes in premenopausal women
   Breast Cancer Res., 16 (6), 499
   DOI 10.1186/s13058-014-0499-2
8. Frydenberg H, Flote VG, Iversen A, Finstad SE, Furberg AS, Torjesen PA, Wilsgaard T, Schlichting E, Ellison PT, Ursin G, Thune I (2014)
   Insulin-like growth factor-1, growth hormone, and daily cycling estrogen are associated with mammographic density in premenopausal women
   Cancer Causes Control, 25 (7), 891-903
   DOI 10.1007/s10552-014-0389-z
9. Gilje B, Nordgard O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B (2014)
   Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
   BMC Cancer, 14, 514
   DOI 10.1186/1471-2407-14-514
10. Grinde MT, Skrbo N, Moestue SA, Rodland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Borresen-Dale AL, Mlandsmo GM, Engebraaten O, Sorlie T, Marangoni E, Gribbestad IS (2014)
    Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
    Breast Cancer Res., 16 (1), R5
    DOI 10.1186/bcr3597
11. Halvorsen AR, Helland A, Fleischer T, Haug KM, Alnaes GIG, Nebdal D, Syljuasen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Borresen-Dale AL, Kristensen V, Edvardsen H (2014)
    Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
    Int. J. Cancer, 135 (9), 2085-2095
    DOI 10.1002/ijc.28862
12. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Roth F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J et al. (2014)
    International study on inter-reader variability for circulating tumor cells in breast cancer
    Breast Cancer Res., 16 (2), R43
    DOI 10.1186/bcr3647
13. Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Maelandsmo GM, Malinen E (2014)
    Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
    Acta Oncol., 53 (8), 1086-1092
    DOI 10.3109/0284186X.2014.934398
14. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mnlandsmo GM, Engebraaten O (2014)
    Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
    Clin. Cancer Res., 20 (2), 404-412
    DOI 10.1158/1078-0432.CCR-13-1865
15. Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Saetersdal AB, Rypdal MC, Schirmer CB, Wist EA, Borgen E (2014)
    Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer
    J. Clin. Oncol., 32 (34), 3848-U245
    DOI 10.1200/JCO.2014.56.9327
16. Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
    Associations Between Tumor Vascularization Assessed by In Vivo DCE-MRI and the Presence of Disseminated Tumor Cells in Bone Marrow in Breast Cancer Patients at the Time of Diagnosis
    J. Magn. Reson. Imaging, 40 (6), 1382-1391
    DOI 10.1002/jmri.24502
17. Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Saeter G, Jorgensen LH, Hall KS (2014)
    Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?
    Acta Oncol., 53 (9), 1180-1187
    DOI 10.3109/0284186X.2014.899433
18. Reiche K, Kasack K, Schreiber S, Luders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Borresen-Dale AL, Hackermuller J, Baumbusch LO (2014)
    Long Non-Coding RNAs Differentially Expressed between Normal versus Primary Breast Tumor Tissues Disclose Converse Changes to Breast Cancer-Related Protein-Coding Genes
    PLoS One, 9 (9), e106076
    DOI 10.1371/journal.pone.0106076
19. Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA (2014)
    Upper Limb Physical Function and Adverse Effects After Breast Cancer Surgery: A Prospective 2.5-Year Follow-Up Study and Preoperative Measures
    Arch. Phys. Med. Rehabil., 95 (5), 875-881
    DOI 10.1016/j.apmr.2013.12.015
20. Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Maelandsmo GM, Sorlie T, Andersen K (2014)
    Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft
    PLoS One, 9 (11), e113278
    DOI 10.1371/journal.pone.0113278

Publications 2013

1. Aure MR, Steinfeld I, Baumbusch LO, Liestol K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Borresen-Dale AL, Lingjaerde OC, Yakhini Z (2013)
   Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data
   PLoS One, 8 (1), e53014
   DOI 10.1371/journal.pone.0053014
2. Barrett ES, Thune I, Lipson SF, Furberg AS, Ellison PT (2013)
   A factor analysis approach to examining relationships among ovarian steroid concentrations, gonadotrophin concentrations and menstrual cycle length characteristics in healthy, cycling women
   Hum. Reprod., 28 (3), 801-811
   DOI 10.1093/humrep/des429
3. Barrett ES, Tran V, Thurston S, Jasienska G, Furberg AS, Ellison PT, Thune I (2013)
   Marriage and motherhood are associated with lower testosterone concentrations in women
   Horm. Behav., 63 (1), 72-79
   DOI 10.1016/j.yhbeh.2012.10.012
4. Edvardsen H, Landmark-Hoyvik H, Reinertsen KV, Zhao X, Grenaker-Alnaes GI, Nebdal D, Syvanen AC, Rodningen O, Alsner J, Overgaard J, Borresen-Dale AL, Fossa SD, Kristensen VN (2013)
   SNP in TXNRD2 Associated With Radiation-Induced Fibrosis: A Study of Genetic Variation in Reactive Oxygen Species Metabolism and Signaling
   Int. J. Radiat. Oncol. Biol. Phys., 86 (4), 791-799
   DOI 10.1016/j.ijrobp.2013.02.025
5. Engebraaten O, Vollan HKM, Borresen-Dale AL (2013)
   Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
   Am. J. Pathol., 183 (4), 1064-1074
   DOI 10.1016/j.ajpath.2013.05.033
6. Kristian A, Nilsen LB, Roe K, Revheim ME, Engebraten O, Mlandsmo GM, Holm R, Malinen E, Seierstad T (2013)
   Dynamic F-18-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
   NUCL. MED. MOLEC. IMAG., 47 (3), 173-180
   DOI 10.1007/s13139-013-0211-y
7. Kristian A, Revheim ME, Qu H, Maelandsmo GM, Engebraten O, Seierstad T, Malinen E (2013)
   Dynamic F-18-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
   Acta Oncol., 52 (7), 1566-1572
   DOI 10.3109/0284186X.2013.813634
8. Laake I, Carlsen MH, Pedersen JI, Weiderpass E, Selmer R, Kirkhus B, Thune I, Veierod MB (2013)
   Intake of trans fatty acids from partially hydrogenated vegetable and fish oils and ruminant fat in relation to cancer risk
   Int. J. Cancer, 132 (6), 1389-1403
   DOI 10.1002/ijc.27737
9. Mikalsen LTG, Dhakal HP, Bruland OS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
   The Clinical Impact of Mean Vessel Size and Solidity in Breast Carcinoma Patients
   PLoS One, 8 (10), e75954
   DOI 10.1371/journal.pone.0075954
10. Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Maelandsmo GM, Akslen LA, Gribbestad IS (2013)
    Low-Molecular Contrast Agent Dynamic Contrast-Enhanced (DCE)-MRI and Diffusion-Weighted (DW)-MRI in Early Assessment of Bevacizumab Treatment in Breast Cancer Xenografts
    J. Magn. Reson. Imaging, 38 (5), 1043-1053
    DOI 10.1002/jmri.24079
11. Moller EK, Kumar P, Voet T, Peterson A, Van Loos P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Borresen-Dale AL, White KP, Nord S, Kristensen VN (2013)
    Next-generation sequencing of disseminated tumor cells
    Front. Oncol., 3, 320
    DOI 10.3389/fonc.2013.00320
12. Olsen K, Danielsen K, Wilsgaard T, Sangvik M, Sollid JUE, Thune I, Eggen AE, Simonsen GS, Furberg AS (2013)
    Obesity and Staphylococcus aureus Nasal Colonization among Women and Men in a General Population
    PLoS One, 8 (5), e63716
    DOI 10.1371/journal.pone.0063716
13. Olsen K, Sangvik M, Simonsen GS, Sollid JUE, Sundsfjord A, Thune I, Furberg AS (2013)
    Prevalence and population structure of Staphylococcus aureus nasal carriage in healthcare workers in a general population. The Tromso Staph and Skin Study
    Epidemiol. Infect., 141 (1), 143-152
    DOI 10.1017/S0950268812000465
14. Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Karesen R, Nesland JM, Naume B (2013)
    Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
    Acta Oncol., 52 (1), 91-101
    DOI 10.3109/0284186X.2012.713508
15. Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B (2013)
    Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome
    Breast Cancer Res. Treat., 138 (2), 485-497
    DOI 10.1007/s10549-013-2439-8
16. Tjessem KH, Johansen S, Malinen E, Reinertsen KV, Danielsen T, Fossa SD, Fossa A (2013)
    Long-term Cardiac Mortality After Hypofractionated Radiation Therapy in Breast
    Int. J. Radiat. Oncol. Biol. Phys., 87 (2), 337-343
    DOI 10.1016/j.ijrobp.2013.05.038
17. Torris C, Thune I, Emaus A, Finstad SE, Bye A, Furberg AS, Barrett E, Jasienska G, Ellison P, Hjartaker A (2013)
    Duration of Lactation, Maternal Metabolic Profile, and Body Composition in the Norwegian EBBA I-Study
    Breastfeed. Med., 8 (1), 8-15
    DOI 10.1089/bfm.2012.0048

Publications 2012

1. Bukowski R, Chlebowski RT, Thune I, Furberg AS, Hankins GDV, Malone FD, D'Alton ME (2012)
   Birth Weight, Breast Cancer and the Potential Mediating Hormonal Environment
   PLoS One, 7 (7), e40199
   DOI 10.1371/journal.pone.0040199
2. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
   Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
   Histopathology, 61 (3), 350-364
   DOI 10.1111/j.1365-2559.2012.04223.x
3. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
   Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
   Histol. Histopath., 27 (10), 1315-1325
4. Engesaeter B, Engebraaten O, Florenes VA, Maelandsmo GM (2012)
   Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
   PLoS One, 7 (9), e45492
   DOI 10.1371/journal.pone.0045492
5. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Kruger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2012)
   In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
   J. Magn. Reson. Imaging, 35 (5), 1098-1107
   DOI 10.1002/jmri.23507
6. Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison PT, Jasienska G, Flote V, Poole EM, Furberg AS (2012)
   Genetic Polymorphism CYP17 rs2486758 and Metabolic Risk Factors Predict Daily Salivary 17 beta-Estradiol Concentration in Healthy Premenopausal Norwegian Women. The EBBA-I Study
   J. Clin. Endocrinol. Metab., 97 (5), E852-E857
   DOI 10.1210/jc.2011-2577
7. Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lonning PE (2012)
   Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
   Breast Cancer Res., 14 (2), R47
   DOI 10.1186/bcr3147
8. Knappskog S, Gansmo LB, Romundstad P, Bjornslett M, Trovik J, Sommerfelt-Pettersen J, Lokkevik E, Tollenaar RAEM, Seynaeve C, Devilee P, Salvesen HB, Dorum A, Hveem K, Vatten L, Lonning PE, Norwegian Breast Canc Grp (2012)
   MDM2 Promoter SNP344T > A (rs1196333) Status Does Not Affect Cancer Risk
   PLoS One, 7 (4), e36263
   DOI 10.1371/journal.pone.0036263
9. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sorlie T, Warnberg F, Haakensen VD, Helland A, Naume B, Perou CM, Haussler D, Troyanskaya OG, Borresen-Dale AL (2012)
   Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
   Proc. Natl. Acad. Sci. U. S. A., 109 (8), 2802-2807
   DOI 10.1073/pnas.1108781108
10. Lindholm EM, Kristian A, Nalwoga H, Kruger K, Nygard S, Akslen LA, Moelandsmo GM, Engebraaten O (2012)
    Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
    Mol. Oncol., 6 (4), 418-427
    DOI 10.1016/j.molonc.2012.03.006
11. Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lonning PE, Naume B (2012)
    Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
    Breast Cancer Res., 14 (4), R117
    DOI 10.1186/bcr3242
12. Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Lingjaerde OC, Borresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2012)
    High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
    Int. J. Cancer, 131 (4), E405-E415
    DOI 10.1002/ijc.26444
13. Molloy TJ, Roepman P, Naume B, van't Veer LJ (2012)
    A Prognostic Gene Expression Profile That Predicts Circulating Tumor Cell Presence in Breast Cancer Patients
    PLoS One, 7 (2), e32426
    DOI 10.1371/journal.pone.0032426
14. Olsen K, Falch BM, Danielsen K, Johannessen M, Sollid JUE, Thune I, Grimnes G, Jorde R, Simonsen GS, Furberg AS (2012)
    Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromso Staph and Skin Study
    Eur. J. Clin. Microbiol. Infect. Dis., 31 (4), 465-473
    DOI 10.1007/s10096-011-1331-x
15. Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
    Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
    BMC Cancer, 12, 616
    DOI 10.1186/1471-2407-12-616
16. Wist EA, Mjaaland I, Lokkevik E, Sommer HH (2012)
    Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
    J. Oncol., 2012, 862921
    DOI 10.1155/2012/862921
17. Ziomkiewicz A, Pawlowski B, Ellison PT, Lipson SF, Thune I, Jasienska G (2012)
    Higher luteal progesterone is associated with low levels of premenstrual aggressive behavior and fatigue
    Biol. Psychol., 91 (3), 376-382
    DOI 10.1016/j.biopsycho.2012.08.001

Publications 2011

1. Bernsdorf M, Ingvar C, Jorgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B (2011)
   Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
   Breast Cancer Res. Treat., 126 (2), 463-470
   DOI 10.1007/s10549-011-1352-2
2. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjonsberg G, Aas T, Schlichting E, Fjosne HE, Nysted A, Lillehaug JR, Lonning PE (2011)
   Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
   PLoS One, 6 (4), e19249
   DOI 10.1371/journal.pone.0019249
3. Dahl AA, Nesvold IL, Reinertsen KV, Fossa SD (2011)
   Arm/shoulder problems and insomnia symptoms in breast cancer survivors: Cross-sectional, controlled and longitudinal observations
   Sleep Med., 12 (6), 584-590
   DOI 10.1016/j.sleep.2011.01.011
4. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2011)
   Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
   Breast Cancer Res. Treat., 125 (3), 729-738
   DOI 10.1007/s10549-010-0911-2
5. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Ronneberg JA, Johnsen H, Navon R, Rodland E, Makela R, Naume B, Perala M, Kallioniemi O, Kristensen VN, Yakhini Z, Borresen-Dale AL (2011)
   miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
   PLoS One, 6 (2), e16915
   DOI 10.1371/journal.pone.0016915
6. Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2011)
   Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
   Eur. Radiol., 21 (6), 1188-1199
   DOI 10.1007/s00330-010-2020-3
7. Fors EA, Bertheussen GF, Thune I, Juvet LK, Elvsaas IKO, Oldervoll L, Anker G, Falkmer U, Lundgren S, Leivseth G (2011)
   Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review
   Psycho-Oncol., 20 (9), 909-918
   DOI 10.1002/pon.1844
8. Grinde MT, Moestue SA, Borgan E, Risa O, Engebraaten O, Gribbestad IS (2011)
   13C High-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
   NMR Biomed., 24 (10), 1243-1252
   DOI 10.1002/nbm.1683
9. Iversen A, Thune I, McTiernan A, Emaus A, Finstad SE, Flote V, Wilsgaard T, Lipson SF, Ellison PT, Jasienska G, Furberg AS (2011)
   Ovarian hormones and reproductive risk factors for breast cancer in premenopausal women: the Norwegian EBBA-I study
   Hum. Reprod., 26 (6), 1519-1529
   DOI 10.1093/humrep/der081
10. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
    Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse-A European Pooled Analysis
    Clin. Cancer Res., 17 (9), 2967-2976
    DOI 10.1158/1078-0432.CCR-10-2515
11. Johansen S, Reinertsen KV, Knutstad K, Olsen DR, Fossa SD (2011)
    Dose distribution in the thyroid gland following radiation therapy of breast cancer-a retrospective study
    Radiat. Oncol., 6, 68
    DOI 10.1186/1748-717X-6-68
12. Kamalakaran S, Varadan V, Russnes HEG, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Karesen R, Prasada KS, Rotti H, Rao R, Rao L, Tang MHE, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB (2011)
    DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables
    Mol. Oncol., 5 (1), 77-92
    DOI 10.1016/j.molonc.2010.11.002
13. Knappskog S, Bjornslett M, Myklebust LM, Huijts PEA, Vreeswijk MP, Edvardsen H, Guo YL, Zhang XM, Yang M, Ylisaukko-oja SK, Alhopuro P, Arola J, Tollenaar RAEM, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Lokkevik E, Salvesen HB, Evans DG, Newman WG, Lin DX, Aaltonen LA, Borresen-Dale AL, Tell GS et al. (2011)
    The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
    Cancer Cell, 19 (2), 273-282
    DOI 10.1016/j.ccr.2010.12.019
14. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
    Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
    Clin. Cancer Res., 17 (13), 4568-4580
    DOI 10.1158/1078-0432.CCR-11-0184
15. Landmark-Hoyvik H, Dumeaux V, Reinertsen KV, Edvardsen H, Fossa SD, Borresen-Dale AL (2011)
    BLOOD GENE EXPRESSION PROFILING OF BREAST CANCER SURVIVORS EXPERIENCING FIBROSIS
    Int. J. Radiat. Oncol. Biol. Phys., 79 (3), 875-883
    DOI 10.1016/j.ijrobp.2010.09.052
16. Moestue SA, Engebraaten O, Gribbestad IS (2011)
    Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy
    Mol. Oncol., 5 (3), 224-241
    DOI 10.1016/j.molonc.2011.04.001
17. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
    The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
    Breast Cancer Res., 13 (3), R61
    DOI 10.1186/bcr2898
18. Nesvold IL, Reinertsen KV, Fossa SD, Dahl AA (2011)
    The relation between arm/shoulder problems and quality of life in breast cancer survivors: a cross-sectional and longitudinal study
    J. Cancer Surviv.-Res. Pract., 5 (1), 62-72
    DOI 10.1007/s11764-010-0156-4
19. Orre IJ, Reinertsen KV, Aukrust P, Dahl AA, Fossa SD, Ueland T, Murison R (2011)
    Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors
    J. Psychosomat. Res., 71 (3), 136-141
    DOI 10.1016/j.jpsychores.2011.04.003
20. Reinertsen KV, Alnaes GIG, Landmark-Hoyvik H, Loge JH, Wist E, Kristensen VN, Fossa SD, Edvardsen H (2011)
    Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway
    Brain Behav. Immun., 25 (7), 1376-1383
    DOI 10.1016/j.bbi.2011.04.001
21. Ronneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Borresen-Dale AL, Tost J, Kristensen V (2011)
    Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer
    Mol. Oncol., 5 (1), 61-76
    DOI 10.1016/j.molonc.2010.11.004
22. Zhao X, Rodland EA, Sorlie T, Naume B, Langerod A, Frigessi A, Kristensen VN, Borresen-Dale AL, Lingjaerde OC (2011)
    Combining Gene Signatures Improves Prediction of Breast Cancer Survival
    PLoS One, 6 (3), e17845
    DOI 10.1371/journal.pone.0017845

Publications 2010

1. Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg AS, Bernstein L, Schlichting E, Thune I (2010)
   Metabolic profile, physical activity, and mortality in breast cancer patients
   Breast Cancer Res. Treat., 121 (3), 651-660
   DOI 10.1007/s10549-009-0603-y
2. Fu YP, Edvardsen H, Kaushiva A, Arhancet JP, Howe TM, Kohaar I, Porter-Gill P, Shah A, Landmark-Hoyvik H, Fossa SD, Ambs S, Naume B, Borresen-Dale AL, Kristensen VN, Prokunina-Olsson L (2010)
   NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations
   Mol. Cancer, 9, 113
   DOI 10.1186/1476-4598-9-113
3. Landmark-Hoyvik H, Reinertsen KV, Loge JH, Kristensen VN, Dumeaux V, Fossa SD, Borresen-Dale AL, Edvardsen H (2010)
   The Genetics and Epigenetics of Fatigue
   PM&R, 2 (5), 456-465
   DOI 10.1016/j.pmrj.2010.04.003
4. Laake I, Thune I, Selmer R, Tretli S, Slattery ML, Veierod MB (2010)
   A Prospective Study of Body Mass Index, Weight Change, and Risk of Cancer in the Proximal and Distal Colon
   Cancer Epidemiol. Biomarkers Prev., 19 (6), 1511-1522
   DOI 10.1158/1055-9965.EPI-09-0813
5. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
   Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
   Mol. Oncol., 4 (2), 169
   DOI 10.1016/j.molonc.2010.01.003
6. Nesvold IL, Fossa SD, Holm I, Naume B, Dahli AA (2010)
   Arm/shoulder problems in breast cancer survivors are associated with reduced health and poorer physical quality of life
   Acta Oncol., 49 (3), 347-353
   DOI 10.3109/02841860903302905
7. Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fossa SD (2010)
   Predictors and course of chronic fatigue in long-term breast cancer survivors
   J. Cancer Surviv.-Res. Pract., 4 (4), 405-414
   DOI 10.1007/s11764-010-0145-7
8. Russnes HG, Vollan HKM, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sorlie T, Borgen E, Rye IH, Langerod A, Chin SF, Teschendorff AE, Stephens PJ, Maner S, Schlichting E, Baumbusch LO, Karesen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Borresen-Dale AL (2010)
   Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients
   Sci. Transl. Med., 2 (38), 38ra47
   DOI 10.1126/scitranslmed.3000611
9. Van Belle V, Van Calster B, Brouckaert O, Bempt IV, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P (2010)
   Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis
   J. Clin. Oncol., 28 (27), 4129-4134
   DOI 10.1200/JCO.2009.26.4200
10. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Borresen-Dale AL, Kristensen VN (2010)
    Allele-specific copy number analysis of tumors
    Proc. Natl. Acad. Sci. U. S. A., 107 (39), 16910-16915
    DOI 10.1073/pnas.1009843107